MaxCyte (MXCT)

• Market cap: $277M
• 1 day: 2.35%
• 5 days: 12.02%
• 1 month: -19.94%
• 3 months: -47.17%
• 6 months: -31.13%
• Year to date: -37.11%
• 1 year: -33.76%
• 5 years: -84.65%
• 10 years: -84.65%
• Sector: Healthcare
• Industry: Medical Devices

About: MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Employees: 114

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

211% more call options, than puts

Call options by funds: $84K | Put options by funds: $27K

50% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 30

13% more capital invested

Capital invested by funds: $268M [Q3] → $302M (+$34M) [Q4]

3.31% more ownership

Funds ownership: 65.4% [Q3] → 68.72% (+3.31%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 21

2% less funds holding

Funds holding: 120 [Q3] → 118 (-2) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $9 245% upside
• Avg. target: $9 245% upside
• High target: $9 245% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Stifel Daniel Arias 11% 1-year accuracy 2 / 19 met price target

245% upside $9

Buy Maintained

12 Mar 2025